Teledyne stock climbs as Q2 earnings beat analyst estimates

Second-quarter sales for Thousand Oaks-based Teledyne Technologies dipped 5 percent to $743.3 million, and net income beat analyst estimates, sending the stock up 2.5 percent in early trading. Net income fell around 10 percent compared to the previous year’s second quarter to $93.7 million, or $2.48 per share, squarely beating analyst predictions of around $2 Read More →
Amgen puts $421M into BeiGene

Thousand Oaks biotech giant Amgen has upped its investment in Chinese oncology research firm BeiGene by $421 million. Amgen’s new investment, announced July 13, will allow the company maintain its ownership interest in BeiGene at 20.3 percent following a direct offering by the Chinese firm. Amgen shares rose more than 1 percent following the news Read More →

Mindbody’s Stollmeyer to be executive chair of the board

This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.

Judge upholds Amgen’s Enbrel patents

This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.

Manchak leaving EVC of SLO

This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.